Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Biography

Meet the Editorial Board Member

Author(s): Veysel Kayser

Volume 23, Issue 11, 2022

Published on: 24 June, 2022

Page: [1313 - 1314] Pages: 2

DOI: 10.2174/138920102311220624142738

Next »
[1]
Kayser V, Datta-Mannan A. (2022) Monoclonal Antibody-Directed Therapy. Australia; MDPI - Open Access Publishing.
[2]
Kayser V. (2022) Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers. Australia; MDPI - Open Access Publishing.
[3]
Komalla V, Haghi M, Kayser V. (2022)..Biologics and Vaccines for Nasal and Pulmonary Drug Delivery.In Dinesh Kumar Chellappan, Kavita Pabreja, Md. Faiyazuddin (Eds.), Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases, (pp. 493-521). Singapore: Springer Nature Singapore..
[4]
Cruz Gonzalez E, Kayser V. (2021). Major Classes of Biotherapeutics.In Iqbal Ramzan (Eds.), ; Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists, Physicians, and Other Health Practitioners (pp 47-69). Hoboken; John Wiley & Sons.
[5]
Kayser V, Sen M. (2021). New Emerging Biotherapies: Cutting-Edge Research to Experimental Therapies. In Iqbal Ramzan (Eds.), Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists, Physicians, and Other Health Practitioners. (pp. 213-236); Hoboken; John Wiley & Sons.
[6]
Kayser V, Reslan M. (2021). Pivotal Biology, Chemistry, Biochemistry, and Biophysical Concepts of Biologics and Biosimilars.In Iqbal Ramzan (Eds.), Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists, Physicians, and Other Health Practitioners. (pp. 89-107. Hoboken: John Wiley & Sons
[7]
Eroglu B, Nuwarda R, Ramzan I, Kayser V. (2022). A Narrative Review of COVID-19 Vaccines. Vaccines 10(1): 62.
[8]
Mckertish C, Kayser V. (2021). Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines 9(8): 872.
[9]
Nuwarda R, Alharbi A. Kayser, V.(2021). An overview of influenza viruses and vaccines. Vaccines 9(9): 1032.
[10]
Cruz E, Sifniotis V, Sumer Bayraktar Z, et al. (2021). Glycan profile analysis of engineered trastuzumab with rationally added glycosylation sequons presents significantly increased glycan complexity. Pharmaceutics 13(11): 1747.
[11]
Tarkistani M, Komalla V, Kayser V. (2021). Recent advances in the use of iron gold hybrid nanoparticles for biomedical applications. Nanomaterials 11(5): 1227.
[12]
Kayser V, Ramzan I. (2021). Vaccines and vaccination: history and emerging issues. Human Vaccines and Immunotherapeutics, 17(12): 5255-68.
[13]
Jefferies M, Rashid H, Hill-Cawthorne G, Kayser V. (2020). A Brief History of Ebolavirus disease: Paving the Way Forward by Learning from the Previous Outbreaks. Infectious Disorders- Drug Targets 20(3): 259-66.
[14]
Reslan M, Sifniotis V, Cruz E, Sumer Bayraktar Z, Cordwell S, Kayser V. (2020). Enhancing the stability of adalimumab by engineering additional glycosylation motifs. International Journal of Biological Macromolecules 158: 189-96.
[15]
Akkoc S, Kayser V. (2019).. Patent Family: Effective catalysts in Suzuki-Miyaura cross-coupling reaction (M50198496).
[16]
Akkoc S, Kayser V. (2019)..Patent Family: Methods and compounds for the treatment of cancer (M50176324).
[17]
Chennamsetty N, Helk B, Kayser V, Trout B, Voynov V. (2010). Methods for identification of sites for IgG conjugation. Patent No. WO 2010141902 A2 20101209..
[18]
Chennamsetty N, Helk B, Kayser V, Trout B, Voynov V. (2009)..Immunoglobulins with reduced aggregation. Patent No. WO 2009155513 A2 20091223..
[19]
Chennamsetty N, Helk B, Trout B, Kayser V, Voynov V. (2009)..Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefore. Patent No. WO 2009155518 A1 20091223..

Rights & Permissions Print Cite
Article Metrics
12
1
© 2025 Bentham Science Publishers | Privacy Policy